The continuing spread of COVID-19 and the associated 21-day lock-down in India has left the clinical trials segment and clinical research organizations (CROs) in the country in uncharted and tricky territory, as in many other parts of the world.
The Indian regulator has now issued a broad notice around managing clinical trials in the context of the coronavirus outbreak,...